Clinical trial results have shown further that two GLP-1 receptor agonists (GLP-1 RAs), exenatide and liraglutide, which are approved for the treatment of hyperglycemia in patients with type 2 diabetes, also produce weight loss in overweight subjects without diabetes
Each 3 mL prefilled, single-patient-use pen contains semaglutide 2 mg (0.68 mg/mL), 4 mg (1.34 mg/mL), or 8 mg (2.68 mg/mL)
Ready to explore peptides
Drug Interactions Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin Oral Medications Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin The risk of hypoglycemia is increased when semaglutide is used in combination with insulin secretagogues (e.g., sulfonylureas) or insulin
The potential for weight loss is interesting, but I think the most interesting reason to pursue glucagon agonism in a multi-receptor agonist is the possibility that you could alter hepatic liver metabolism and potentially decrease fatty acid accumulation and hypertriglyceridemia.
Stephen Lovekin/Shutterstock "It does affect you mentally," she told PORTER in a Dec
